Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Company profile
Ticker
BMRA
Exchange
Website
CEO
Mr. Zackary S. Irani
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
Corporate docs
Subsidiaries
BioEurope GmbH • Biomerica de Mexico ...
IRS number
952645573
BMRA stock data
Latest filings (excl ownership)
10-Q
2025 Q1
Quarterly report
15 Oct 24
DEF 14A
Definitive proxy
30 Sep 24
PRE 14A
Preliminary proxy
20 Sep 24
10-K
2024 FY
Annual report
28 Aug 24
8-K
Departure of Directors or Certain Officers
28 Jun 24
424B5
Prospectus supplement for primary offering
10 May 24
8-K
Entry into a Material Definitive Agreement
10 May 24
10-Q
2024 Q3
Quarterly report
12 Apr 24
10-Q
2024 Q2
Quarterly report
16 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Aug 24 | May 24 | Feb 24 | Nov 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | May 24 | May 23 | May 22 | May 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.82 mm | 2.82 mm | 2.82 mm | 2.82 mm | 2.82 mm | 2.82 mm |
Cash burn (monthly) | 450.00 k | 430.67 k | 456.00 k | 542.00 k | 448.00 k | 419.25 k |
Cash used (since last report) | 774.77 k | 741.49 k | 785.10 k | 933.17 k | 771.33 k | 721.83 k |
Cash remaining | 2.05 mm | 2.08 mm | 2.03 mm | 1.89 mm | 2.05 mm | 2.10 mm |
Runway (months of cash) | 4.5 | 4.8 | 4.5 | 3.5 | 4.6 | 5.0 |
Institutional ownership, Q2 2024
16.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 26 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 920.65 mm |
Total shares | 2.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Granahan Investment Management | 860.46 k | $378.43 mm |
Palm Management | 571.43 k | $1.56 mm |
Russell Investments | 226.12 k | $99.45 mm |
Vanguard | 214.66 k | $94.41 mm |
BLK BlackRock | 149.08 k | $65.57 mm |
Geode Capital Management | 126.51 k | $55.65 mm |
Susquehanna International | 101.74 k | $44.75 mm |
HRT Financial | 79.20 k | $34.00 k |
Perritt Capital Management | 70.00 k | $30.79 mm |
Fore Capital | 59.68 k | $26.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Barbieri Allen | Common Stock | Gift | Dispose G | No | No | 0 | 15,000 | 0.00 | 78,337 |
13 Dec 23 | Catherine Coste | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Moatazedi David | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Kenny John P. | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Jane Emerson | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
27 Jun 23 | Barbieri Allen | Common Stock | Gift | Dispose G | No | No | 0 | 8,000 | 0.00 | 93,327 |